Please assess the completion status of the following clinical trial:

Trial Title: Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers (as concluded from the medical history, physical examination, and clinical judgment) aged 19 to 50 years old~* Females using a reliable method of contraception (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy test will be required before administration of each dose of vaccine~* Signed informed consent~* Subjects able to understand and comply with the study protocol and complete the Adverse Event Form~* Subjects able to attend the scheduled visits~* Subjects with normal pre-screening values. If a subjects prescreening samples lie outside the reference values he/she will only be included in the study based upon the medical evaluation of the clinical investigator~Exclusion Criteria:~* Persons with a history of anaphylaxis or serious reactions to any vaccine~* Persons with known hypersensitivity to any of the vaccine components~* Persons who have had a temperature \>38oC during the previous 72 hours~* Persons who have had an acute respiratory infection during the last 7 days~* Women who are pregnant or breast-feeding~* Persons with chronic illness at any stage that could interfere with trial conduct or compliance~* Persons who have received blood products or immunoglobulins parenterally during the previous 3 months~* Persons who have been vaccinated with any vaccine during the 4 weeks preceding the first trial vaccination~* Persons with known or suspected immunosuppressive disease or who use systemic immunosuppressive drugs~* Persons taking immunostimulant therapy~* Persons involved in another clinical trial during the last month.~* Suspected non-compliance

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 30µg HA vaccine Intramuscularly administered
- 2 (Type: ACTIVE_COMPARATOR): 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
- 3 (Type: ACTIVE_COMPARATOR): 7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
- 4 (Type: ACTIVE_COMPARATOR): 30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered

Based on this trial design, predict the completion outcome and termination type (if applicable).